| Literature DB >> 19735543 |
Thomas W Jax1, Ansgar J Peters, Gunnar Plehn, Frank-Chris Schoebel.
Abstract
BACKGROUND: Thrombosis is regarded to be a key factor in the development of acute coronary syndromes in patients with coronary artery disease (CAD). We hypothesize, that hemostatic and rheological risk factors may be of major relevance for the incidence and the risk stratification of these patients.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19735543 PMCID: PMC2743654 DOI: 10.1186/1475-2840-8-48
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
patient characteristics
| clinical event | without clinical event | ||
|---|---|---|---|
| n = 88 | n = 150 | p - value | |
| age (in years) | 58 ± 10 | 56 ± 11 | n.s. |
| Male (%) | 85 | 84 | n.s. |
| hypertension (%) | 59 | 52 | n.s. |
| diabetes mellitus | 31 | 11 | <0,001 |
| hyperlipidemia (%) | 78 | 78 | n.s. |
| hypercholesterinemia (%) | 69 | 70 | n.s. |
| hypertriglyceridemia (%) | 29 | 32 | n.s. |
| history of smoking or smoking (%) | 69 | 66 | n.s. |
| positive family history (%) | 44 | 42 | n.s. |
| history of myokardial infarction (%) | 44 | 51 | n.s. |
| history of ACB operation (%) | 10 | 5,4 | n.s. |
| history of PTCA (%) | 57 | 61 | n.s. |
| nitrates (%) | 87 | 80 | n.s. |
| calcium channel blockers (%) | 50 | 41 | n.s. |
| betablockers (%) | 41 | 46 | n.s. |
| ace-inhibitors (%) | 31 | 28 | n.s. |
| thrombocytaggregationinhibitors (%) | 73 | 78 | n.s. |
| lipid lowering medication (%) | 37 | 45 | n.s. |
| insuline (%) | 1,1 | 1,4 | n.s. |
| oral andiabetic medication (%) | 10 | 3,4 | p < 0,05 |
Figure 1clinical events in 243 patients. Elective revascularizations include aorto-coronary bypass operation and angioplasty, acute events include unstable angina pectoris, acute myocardial infarction and cardiac death.
severity and extent of coronary atherosclerosis
| clinical event | without clinical event | p-value | |
|---|---|---|---|
| n = 88 | n = 150 | ||
| 1- vessel disease (%) | 28 | 51 | |
| 2 - vessel disease (%) | 36 | 28 | |
| 3 - vessel disease (%) | 36 | 22 | p < 0,01 |
| total score | 1,67 ± 0,71 | 1,31 ± 0,73 | p < 0,001 |
| proximal score | 1,83 ± 0,74 | 1,49 ± 0,77 | p < 0,001 |
| distal score | 1,43 ± 0,79 | 1,03 ± 0,70 | p < 0,001 |
parameters of metabolism, hemostasis endogenous fibrinolysis and blood rheology
| clinical event | without clinical event | p-value | |
|---|---|---|---|
| n = 88 | n = 150 | ||
| total cholesterol (mg/dl) | 243 ± 49 | 238 ± 44 | n.s. |
| hdl - cholesterol(mg/dl) | 44 ± 11 | 45 ± 12 | n.s. |
| ldl - cholesterol(mg/dl) | 182 ± 49 | 173 ± 41 | n.s. |
| triglycerides (mg/dl) | 209 ± 143 | 185 ± 113 | n.s. |
| lipoproteine (a) (mg/dl) | 32 ± 39 | 34 ± 41 | n.s. |
| uric acid (mg/dl) | 5,8 ± 1,6 | 6,6 ± 1,7 | n.s. |
| glucose (mg/dl) | 108 ± 51 | 92 ± 35 | <0,05 |
| tissue -plasminogenactivator (μg/l) | 9,3 ± 3,5 | 8,2 ± 3,0 | <0,05 |
| plasminogenaktivator-inhibitore (U/ml) | 4,9 ± 2,5 | 4,9 ± 3,0 | n.s. |
| fibrinogen (mg/dl) | 330 ± 65 | 319 ± 70 | n.s. |
| plasma viscosity (mPa × s-1) | 1,3 ± 0,1 | 1,3 ± 0,2 | n.s. |
| red blood cell aggregation M (E) | 7,7 ± 2,4 | 7,5 ± 2,3 | n.s. |
| red blood cell aggregation M1 (E) | 12,4 ± 2,9 | 12,3 ± 3,0 | n.s. |
| hematocrit (%) | 43,6 ± 3,2 | 43,1 ± 3,1 | n.s. |
Figure 2clinical events for patients with and without diabetes mellitus. Elective revascularizations include aorto-coronary bypass operation and angioplasty, acute events include unstable angina pectoris, acute myocardial infarction and cardiac death.
parameters of metabolism, hemostasis, endogenous fibrinolysis and blood rheology for patients with and without diabetes mellitus
| diabetes mellitus | non-diabetic patients | p-value | |
|---|---|---|---|
| n = 44 | n = 194 | ||
| total cholesterol (mg/dl) | 254 ± 69 | 239 ± 43 | n.s. |
| hdl - cholesterol(mg/dl) | 42 ± 13 | 45 ± 12 | <0,05 |
| ldl - cholesterol(mg/dl) | 188 ± 55 | 173 ± 43 | <0,05 |
| triglycerides (mg/dl) | 257 ± 204 | 183 ± 103 | <0,05 |
| lipoproteine (a) (mg/dl) | 22 ± 33 | 36 ± 42 | <0,05 |
| glucose (mg/dl) | 157 ± 67 | 88 ± 12 | <0,0001 |
| tissue -plasminogenactivator (μg/l) | 8,9 ± 3,7 | 8,4 ± 3,0 | n.s. |
| plasminogenaktivator-inhibitore (U/ml) | 6,1 ± 5,2 | 4,8 ± 2,7 | <0,05 |
| fibrinogen (mg/dl) | 351 ± 76 | 312 ± 64 | <0,01 |
| plasma viscosity (mPa × s-1) | 1,38 ± 0,23 | 1,31 ± 0,16 | <0,01 |
| red blood cell aggregation M (E) | 8,7 ± 2,1 | 7,3 ± 2,0 | <0,05 |
| red blood cell aggregation M1 (E) | 13,2 ± 2,5 | 12,1 ± 3,1 | <0,05 |
Figure 3Rheology in diabetic patients. Between Patients with and without type 2 diabetes mellitus significant differences were found for fibrinogen (A), red blood cell (RBC) aggregation (B), plasma viscosity (C) and Plasminogenactivator-Inhibitor (PAI) (D).
Figure 4Balance and dysbalance of hemostasis in diabetes.